Key Findings
3,132
Active providers
across 8 countries
78%
Verified listings
2,444 providers
97
Compounds tracked
19 with 100+ providers
49 / 51
US states covered
only WV + SD under 10
Provider Landscape
Provider type distribution
Clinics and 503A compounding pharmacies account for 94.2% of all active listings. Telehealth-only platforms represent 2.0% of the directory — a segment that has grown significantly since the post-pandemic shift toward remote prescribing.
78%
Verification rate
2,444 of 3,132 listings independently verified
68
Telehealth-capable
Providers that accept remote patients across state lines
924
503A pharmacies
Compounding pharmacies dispensing peptide compounds under 503A
Most-Offered Compounds
Providers stocking each compound (top 10)
GLP-1 dominance: Semaglutide (725) and Tirzepatide (478) together account for more provider associations than any other single category — a structural shift driven by FDA-approved weight-loss drug demand spilling into compounding channels after the 2023–2024 shortage period.
Recovery compounds hold steady: BPC-157 (569) and TB-500 (278) remain the top recovery compounds despite no FDA approval pathway, sustained by sports medicine clinic demand and the compounding pharmacy channel.
Of the 97 tracked compounds, 19 have 100 or more active providers — indicating meaningful commercial availability, not just catalog listings.
Category Coverage
Providers active in each research category
Fat Loss / GLP-1 leads by provider count (1,023) despite having the fewest compounds (10) — reflecting high GLP-1 concentration per peptide. Longevity has the broadest compound diversity (18 peptides) but narrower provider penetration relative to compound count, suggesting an emerging-market dynamic where supply is building ahead of mainstream demand.
Geographic Distribution
US — providers by state (top 10)
Texas (226) and California (208) lead by a wide margin. The Sun Belt dominates the top 10, with Texas, Florida, Arizona, Tennessee, and Georgia all appearing — consistent with higher rates of functional medicine and compounding pharmacy density in those states.
Peptide deserts — US states with fewer than 10 providers
West Virginia
7 providers
South Dakota
8 providers
49 of 51 US territories have ≥10 active providers. True access gaps are minimal in the US — the larger barrier is awareness and prescribing, not geographic supply.
International coverage
| Country | Providers | Compounds offered |
|---|---|---|
| 🇺🇸United States | 2,731 | 96 |
| 🇬🇧United Kingdom | 138 | 57 |
| 🇨🇦Canada | 120 | 42 |
| 🇦🇺Australia | 112 | 34 |
| 🇳🇿New Zealand | 26 | 3 |
The US accounts for 87.2% of the directory. UK and Canada show strong compound depth relative to provider count — UK providers average 1.2 compounds per provider vs 0.8 for US providers — suggesting international providers tend to offer a broader range per clinic. Australian and Canadian markets reflect similar regulatory contexts and comparable compounding frameworks.
Methodology
All data in this report is sourced from the PeptideBase provider database, a structured directory of clinics, telehealth platforms, compounding pharmacies, and online vendors that offer peptide therapy services or research compounds. The dataset reflects providers with an active listing status as of May 3, 2026.
Provider verification is conducted by the PeptideBase team and involves cross-referencing the provider's website, licensing information, and compound availability claims. Verification does not constitute an endorsement and does not assess clinical competence or product quality.
Compound associations are established when a provider lists a compound as in-stock or available on request. Associations are reviewed for accuracy during the verification process but may not reflect real-time inventory.
Geographic data is derived from provider-reported location fields. Telehealth providers may serve patients outside their listed state or country — the directory reflects physical location of the provider, not patient catchment area.
This report is for informational purposes only. PeptideBase does not provide medical advice. All compound and provider information is educational and should not be used as the basis for medical decisions. Consult a licensed healthcare provider before initiating any peptide therapy.
Explore the full dataset
3,132 providers. 97 compounds. Search the directory.
Every stat in this report is drawn from the live PeptideBase directory. Browse by compound, location, or provider type — or use the matching questionnaire to find relevant providers for a specific research context.